Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison

Journal of Comparative Effectiveness Research
K Jack IshakJuan W Valle

Abstract

A matching-adjusted indirect comparison (MAIC) of sunitinib and everolimus has been previously reported based on the RADIANT-3 everolimus trial. We performed an analysis using updated overall survival (OS) data based on sunitinib's trial (A6181111). The MAIC matched on all baseline characteristics available from both studies. An anchored MAIC was performed for progression-free survival (PFS); an unanchored analysis was deemed more appropriate for OS due to crossover in both trials. A hazard ratio for sunitinib versus everolimus was derived from adjusted (weighted) sunitinib effects compared with the observed results for everolimus. The adjusted hazard ratio for sunitinib versus everolimus was 0.85 (0.39-1.89) for PFS and 0.82 (0.53-1.27) for OS. Findings indicate comparable PFS and OS with sunitinib and everolimus.

References

Jul 15, 2005·Health Technology Assessment : HTA·A M GlennyUNKNOWN International Stroke Trial Collaborative Group
Sep 5, 2008·PharmacoEconomics·Alex SuttonKeith Abrams
Feb 11, 2011·The New England Journal of Medicine·Eric RaymondPhilippe Ruszniewski
Feb 11, 2011·The New England Journal of Medicine·James C YaoUNKNOWN RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group
Oct 12, 2011·BMC Medical Research Methodology·Martin W Hoyle, William Henley
Feb 9, 2012·Nature Reviews. Gastroenterology & Hepatology·Roeland F de WildeAnirban Maitra
Dec 10, 2013·Experimental Hematology & Oncology·James SignorovitchPeter Metrakos
Aug 15, 2014·The Oncologist·Francesco PanzutoGianfranco Delle Fave
Jun 17, 2015·The Lancet. Respiratory Medicine·Sean Cleghorn
Dec 13, 2016·Cancer Chemotherapy and Pharmacology·Changhoon YooBaek-Yeol Ryoo
Jan 24, 2018·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·Maria RinzivilloFrancesco Panzuto

❮ Previous
Next ❯

Software Mentioned

RADIANT
ENGAUGE

Related Concepts

Related Feeds

Adenoma, Islet Cell

Islet Cell Adenoma arises in the islet cells, which are insulin producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Adenoma here.

Carcinoma, Islet Cell (Keystone)

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arise in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on islet cell carcinoma in this feed.

Carcinoma, Islet Cell

Islet Cell Carcinoma or Pancreatic Neuroendocrine Tumours arises in the hormone producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Carcinoma here.